• US therapeutic: $649M (+4% QoQ, +6% YoY) • US cosmetic: $453M (+17% QoQ*, +7% YoY) -- US total: $1.102B (59% therapeutic; 41% cosmetic) was 74% of worldwide total
*In the US market, botulinum-toxin sales for cosmetic indications are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.